309 related articles for article (PubMed ID: 27170187)
1. Design of a small molecule against an oncogenic noncoding RNA.
Velagapudi SP; Cameron MD; Haga CL; Rosenberg LH; Lafitte M; Duckett DR; Phinney DG; Disney MD
Proc Natl Acad Sci U S A; 2016 May; 113(21):5898-903. PubMed ID: 27170187
[TBL] [Abstract][Full Text] [Related]
2. Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit.
Costales MG; Haga CL; Velagapudi SP; Childs-Disney JL; Phinney DG; Disney MD
J Am Chem Soc; 2017 Mar; 139(9):3446-3455. PubMed ID: 28240549
[TBL] [Abstract][Full Text] [Related]
3. Precise Small Molecule Degradation of a Noncoding RNA Identifies Cellular Binding Sites and Modulates an Oncogenic Phenotype.
Li Y; Disney MD
ACS Chem Biol; 2018 Nov; 13(11):3065-3071. PubMed ID: 30375843
[TBL] [Abstract][Full Text] [Related]
4. A general fragment-based approach to identify and optimize bioactive ligands targeting RNA.
Suresh BM; Li W; Zhang P; Wang KW; Yildirim I; Parker CG; Disney MD
Proc Natl Acad Sci U S A; 2020 Dec; 117(52):33197-33203. PubMed ID: 33318191
[TBL] [Abstract][Full Text] [Related]
5. Rational Design of Small Molecules Targeting Oncogenic Noncoding RNAs from Sequence.
Disney MD; Angelbello AJ
Acc Chem Res; 2016 Dec; 49(12):2698-2704. PubMed ID: 27993012
[TBL] [Abstract][Full Text] [Related]
6. Approved Anti-cancer Drugs Target Oncogenic Non-coding RNAs.
Velagapudi SP; Costales MG; Vummidi BR; Nakai Y; Angelbello AJ; Tran T; Haniff HS; Matsumoto Y; Wang ZF; Chatterjee AK; Childs-Disney JL; Disney MD
Cell Chem Biol; 2018 Sep; 25(9):1086-1094.e7. PubMed ID: 30251629
[TBL] [Abstract][Full Text] [Related]
7. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
[TBL] [Abstract][Full Text] [Related]
8. Association of a peptoid ligand with the apical loop of pri-miR-21 inhibits cleavage by Drosha.
Diaz JP; Chirayil R; Chirayil S; Tom M; Head KJ; Luebke KJ
RNA; 2014 Apr; 20(4):528-39. PubMed ID: 24497550
[TBL] [Abstract][Full Text] [Related]
9. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
[TBL] [Abstract][Full Text] [Related]
10. microRNA-200c downregulates XIAP expression to suppress proliferation and promote apoptosis of triple-negative breast cancer cells.
Ren Y; Han X; Yu K; Sun S; Zhen L; Li Z; Wang S
Mol Med Rep; 2014 Jul; 10(1):315-21. PubMed ID: 24821285
[TBL] [Abstract][Full Text] [Related]
11. DNA-encoded library versus RNA-encoded library selection enables design of an oncogenic noncoding RNA inhibitor.
Benhamou RI; Suresh BM; Tong Y; Cochrane WG; Cavett V; Vezina-Dawod S; Abegg D; Childs-Disney JL; Adibekian A; Paegel BM; Disney MD
Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35110406
[TBL] [Abstract][Full Text] [Related]
12. Defining RNA-Small Molecule Affinity Landscapes Enables Design of a Small Molecule Inhibitor of an Oncogenic Noncoding RNA.
Velagapudi SP; Luo Y; Tran T; Haniff HS; Nakai Y; Fallahi M; Martinez GJ; Childs-Disney JL; Disney MD
ACS Cent Sci; 2017 Mar; 3(3):205-216. PubMed ID: 28386598
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development.
Jin C; Yan B; Lu Q; Lin Y; Ma L
Tumour Biol; 2016 Jun; 37(6):7383-94. PubMed ID: 26676637
[TBL] [Abstract][Full Text] [Related]
14. Targeted Degradation of a Hypoxia-Associated Non-coding RNA Enhances the Selectivity of a Small Molecule Interacting with RNA.
Costales MG; Suresh B; Vishnu K; Disney MD
Cell Chem Biol; 2019 Aug; 26(8):1180-1186.e5. PubMed ID: 31130520
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
16. Targeting the production of oncogenic microRNAs with multimodal synthetic small molecules.
Vo DD; Staedel C; Zehnacker L; Benhida R; Darfeuille F; Duca M
ACS Chem Biol; 2014 Mar; 9(3):711-21. PubMed ID: 24359019
[TBL] [Abstract][Full Text] [Related]
17. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
18. siRNA release from pri-miRNA scaffolds is controlled by the sequence and structure of RNA.
Galka-Marciniak P; Olejniczak M; Starega-Roslan J; Szczesniak MW; Makalowska I; Krzyzosiak WJ
Biochim Biophys Acta; 2016 Apr; 1859(4):639-49. PubMed ID: 26921501
[TBL] [Abstract][Full Text] [Related]
19. Inforna 2.0: A Platform for the Sequence-Based Design of Small Molecules Targeting Structured RNAs.
Disney MD; Winkelsas AM; Velagapudi SP; Southern M; Fallahi M; Childs-Disney JL
ACS Chem Biol; 2016 Jun; 11(6):1720-8. PubMed ID: 27097021
[TBL] [Abstract][Full Text] [Related]
20. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
